Video
Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC
Author(s):
Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).
Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).
Lenvatinib is often used in both first- and second-line settings, Cabanillas explains.
In clinical practice, Cabanillas often uses lenvatinib versus sorafenib in patients with aggressive disease that is rapidly progressing. However, both lenvatinib and sorafenib can be used as first-line treatments, she adds.
<<<
View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium
